Use novel properties of nanoparticles to engineer and progress to the clinic 2nd generation therapeutics to tackle major human diseases including cancer, malaria and asthma

利用纳米颗粒的新特性来设计第二代疗法并将其推向临床，以应对包括癌症、疟疾和哮喘在内的主要人类疾病

• 批准号: nhmrc : GNT1059409
• 负责人: Prof Magdalena Plebanski
• 金额: $ 60.14万
• 依托单位: RMIT University
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/use-novel-properties-malaria-asthma/1344690
• 关键词: Use; novel; properties; nanoparticles; engineer

Vaccines require adjuvants to be effective. Despite decades of research there is only one adjuvant approved for broad use in humans. Based on our prior findings I will engage new principles in nanotechnology, and deepen understanding of immune imprinting in various organs of the body including the lung, to develop 2nd generation broadly useful nanoadjuvants able to effectively treat cancer and malaria.

疫苗需要佐剂才能有效。尽管经过数十年的研究，但只有一种佐剂被批准广泛用于人类。基于我们先前的发现，我将从事纳米技术的新原理，并加深对包括肺在内的身体各器官中免疫印记的理解，以开发能够有效治疗癌症和疟疾的第二代广泛有用的纳米佐剂。